Catalyst Wire Dossier Catalyst Wire Dossier

Sf-RVN Cell Recombinant Trivalent Poliomyelitis Vaccine

Recombinant trivalent poliovirus vaccine · CanSino Biologics Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Sf-RVN Cell Recombinant Trivalent Poliomyelitis Vaccine, covering 2024-12-04 to 2024-12-04. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults [Phase 1]

See pricing